lanreotide acetate
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
NeuroEndocrine Tumours
Conditions
NeuroEndocrine Tumours
Trial Timeline
May 1, 2014 → Jun 1, 2017
NCT ID
NCT02075606About lanreotide acetate
lanreotide acetate is a approved stage product being developed by Ipsen for NeuroEndocrine Tumours. The current trial status is completed. This product is registered under clinical trial identifier NCT02075606. Target conditions include NeuroEndocrine Tumours.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02075606 | Approved | Completed |
Competing Products
20 competing products in NeuroEndocrine Tumours
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [203Pb]VMT-α-NET + [212Pb]VMT-α-NET | Perspective Therapeutics | Phase 1/2 | 33 |
| [203Pb]VMT-α-NET | Perspective Therapeutics | Phase 1 | 25 |
| [212Pb] VMT-α-NET | Perspective Therapeutics | Phase 1 | 25 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| Abemaciclib | Eli Lilly | Phase 2 | 52 |
| Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide. | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Famitinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| 68Ga-DOTATOC | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Olaparib | AstraZeneca | Phase 2 | 52 |
| Avelumab | Merck | Phase 1/2 | 41 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab Injection | Merck | Phase 2 | 52 |
| Carboplatin + Cisplatin + Docetaxel + Etoposide + Pembrolizumab | Merck | Phase 1 | 33 |
| Avelumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Lenvatinib | Merck | Phase 2 | 52 |
| Avelumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Irinotecan + Paclitaxel | Merck | Phase 2 | 52 |
| MK-0646 | Merck | Phase 2 | 52 |